Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 416

1.

Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?

Bergmann F, Breinig M, Höpfner M, Rieker RJ, Fischer L, Köhler C, Esposito I, Kleeff J, Herpel E, Ehemann V, Friess H, Schirmacher P, Kern MA.

Am J Gastroenterol. 2009 Jan;104(1):171-81. doi: 10.1038/ajg.2008.33.

PMID:
19098866
2.

Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas.

Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV.

Mod Pathol. 2005 Oct;18(10):1329-35.

3.

Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.

Mayer P, Harjung A, Breinig M, Fischer L, Ehemann V, Malz M, Scherübl H, Britsch S, Werner J, Kern MA, Bläker H, Schirmacher P, Bergmann F.

Endocr Relat Cancer. 2012 May 3;19(3):217-32. doi: 10.1530/ERC-11-0227. Print 2012 Jun.

4.

Fundamental differences in the neural invasion behavior of pancreatic endocrine tumors: relevance for local recurrence rates?

Bergmann F, Ceyhan GO, Rieker RJ, Esposito I, Fischer L, Herpel E, Friess H, Schirmacher P, Kern MA.

Hum Pathol. 2009 Jan;40(1):50-7. doi: 10.1016/j.humpath.2008.06.021. Epub 2008 Sep 11.

PMID:
18789481
5.

Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.

Fjällskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET.

Clin Cancer Res. 2003 Apr;9(4):1469-73.

6.

p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior.

Canavese G, Azzoni C, Pizzi S, Corleto VD, Pasquali C, Davoli C, Crafa P, Delle Fave G, Bordi C.

Hum Pathol. 2001 Oct;32(10):1094-101.

PMID:
11679944
7.

Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo.

Xu XF, Xie CG, Wang XP, Liu J, Yu YC, Hu HL, Guo CY.

Tohoku J Exp Med. 2008 Jun;215(2):149-57.

8.
9.
10.

Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer.

Lanza-Jacoby S, Burd R, Rosato FE Jr, McGuire K, Little J, Nougbilly N, Miller S.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6161-9.

11.

Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors.

Shida T, Kishimoto T, Furuya M, Nikaido T, Koda K, Takano S, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Tanizawa T, Nakatani Y, Miyazaki M.

Cancer Chemother Pharmacol. 2010 Apr;65(5):889-93. doi: 10.1007/s00280-009-1094-6. Epub 2009 Aug 6.

PMID:
19657638
12.

Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity.

Lev-Ari S, Starr A, Vexler A, Karaush V, Loew V, Greif J, Fenig E, Aderka D, Ben-Yosef R.

Anticancer Res. 2006 Nov-Dec;26(6B):4423-30.

13.

Expression of ERRP in normal and neoplastic pancreata and its relationship to clinicopathologic parameters in pancreatic adenocarcinoma.

Feng J, Adsay NV, Kruger M, Ellis KL, Nagothu K, Majumdar AP, Sarkar FH.

Pancreas. 2002 Nov;25(4):342-9.

PMID:
12409827
14.

PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.

Long KB, Srivastava A, Hirsch MS, Hornick JL.

Am J Surg Pathol. 2010 May;34(5):723-9. doi: 10.1097/PAS.0b013e3181da0a20.

PMID:
20414099
15.

Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas.

Bloomer CW, Kenyon L, Hammond E, Hyslop T, Andrews DW, Curran WJ, Dicker AP.

Am J Clin Oncol. 2003 Aug;26(4):S75-80.

PMID:
12902861
16.

Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.

Jia RP, Xu LW, Su Q, Zhao JH, Li WC, Wang F, Xu Z.

Asian J Androl. 2008 Sep;10(5):758-64. doi: 10.1111/j.1745-7262.2008.00423.x.

17.

Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.

Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ, Brekken RA.

Clin Cancer Res. 2012 Sep 15;18(18):5031-42. doi: 10.1158/1078-0432.CCR-12-0453. Epub 2012 Jul 24.

18.

Claudin expression in rectal well-differentiated endocrine neoplasms (carcinoid tumors).

Ishida M, Kushima R, Okabe H.

Oncol Rep. 2009 Jan;21(1):113-7.

PMID:
19082451
19.

The antimetastatic role of thrombomodulin expression in islet cell-derived tumors and its diagnostic value.

Iino S, Abeyama K, Kawahara K, Yamakuchi M, Hashiguchi T, Matsukita S, Yonezawa S, Taniguchi S, Nakata M, Takao S, Aikou T, Maruyama I.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6179-88.

20.

Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.

Dittmann KH, Mayer C, Ohneseit PA, Raju U, Andratschke NH, Milas L, Rodemann HP.

Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):203-12. Epub 2007 Nov 8.

PMID:
17996386
Items per page

Supplemental Content

Write to the Help Desk